Medtronic (NYSE:MDT) has announced that the FDA has approved Vanta, its recharge-free implantable neurostimulator (INS).
With a device life that can be optimized up to 11 years, Vanta can offer nearly twice the device life compared to rival primary cell devices, the company said.
Compared to PrimeAdvanced, Medtronic's previous generation recharge-free device, Vanata is 20% smaller and can drive a 10% increase in longevity.
“Vanta INS represents a welcome addition to my portfolio of available treatment options,” noted Krishnan Chakravarthy, interventional pain management physician based in San Diego.
"The extended battery life, broad MRI compatibility and personalized relief through AdaptiveStim technology allow for a more hassle-free experience and greater freedom for my patients as we manage their chronic pain" Chakravarthy added.
Medtronic’s Neuroscience Portfolio formerly identified as the Restorative Therapies Group recorded ~$8.2B in revenue for fiscal 2021 with ~6.1% YoY growth on a reported basis.